IUPAC/Chemical Name
Benzamide, 2,3-dimethoxy-N-((3-exo)-8-(phenylmethyl)-8-azabicyclo(3.2.1)oct-3-yl)-
InChi Key
PCIWCYUKRZFCMF-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H28N2O3/c1-27-21-10-6-9-20(22(21)28-2)23(26)24-17-13-18-11-12-19(14-17)25(18)15-16-7-4-3-5-8-16/h3-10,17-19H,11-15H2,1-2H3,(H,24,26)
SMILES Code
O=C(NC1CC(N2CC3=CC=CC=C3)CCC2C1)C4=CC=CC(OC)=C4OC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
380.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Strolin Benedetti M, Dow J, Dostert S, Parisy D, Rumigny JF. Localization of a new benzamide derivative, tropapride and of 1-sulpiride, in the pituitary gland of the rat. J Pharmacol. 1984 Oct-Dec;15(4):433-8. PubMed PMID: 6543239.
2: Collin S, Vercauteren DP, Vanderveken D, Evrard G, Durant F. Structural requirements of Na+-dependent antidopaminergic agents: Tropapride, Piquindone, Zetidoline, and Metoclopramide. Comparison with Na+-independent ligands. J Comput Aided Mol Des. 1989 Mar;3(1):39-53. PubMed PMID: 2715795.
3: Damhaut P, Cantineau R, Lemaire C, Plenevaux A, Christiaens L, Guillaume M. 2- and 4-[18F]fluorotropapride, two specific D2 receptor ligands for positron emission tomography: N.C.A. syntheses and animal studies. Int J Rad Appl Instrum A. 1992 Oct;43(10):1265-74. PubMed PMID: 1330979.
4: Rumigny JF, Strolin Benedetti M, Dostert P. Investigation on central dopaminergic receptors (D-2) using the antagonistic properties of new benzamides. J Pharm Pharmacol. 1984 Jun;36(6):373-7. PubMed PMID: 6146667.
5: Wurch T, Boutet-Robinet EA, Palmier C, Colpaert FC, Pauwels PJ. Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs. J Pharmacol Exp Ther. 2003 Jan;304(1):380-90. PubMed PMID: 12490615.
6: Prinssen EP, Kleven MS, Koek W. Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl). 1999 May;144(1):20-9. PubMed PMID: 10379620.
7: Pauwels PJ, Koek W. Atypical kinetics for a series of putative dopamine antagonists to reverse the low-magnitude Ca2+ phase in the dopamine-bound D2short receptor state. Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):82-5. Epub 2001 Oct 31. PubMed PMID: 11862337.
8: Jalfre M, Bucher B, Dorme N, Mocquet G, Porsolt RD. Neuropharmacological profile of MD 790501, a new benzamide derivative. Arch Int Pharmacodyn Ther. 1983 Aug;264(2):232-56. PubMed PMID: 6139097.
9: Pauwels PJ, Finana F, Tardif S, Wurch T, Colpaert FC. Dynamic dopamine-antagonist interactions at recombinant human dopamine D(2short) receptor: dopamine-bound versus antagonist-bound receptor states. J Pharmacol Exp Ther. 2001 Apr;297(1):133-40. PubMed PMID: 11259537.
